UK: Patchy Report From A Gynaecology Conference Is Enough To Put A Bullet In Richter Gedeon’s Morning After Pill Patent

Last Updated: 11 July 2014
Article by Richard Newell and Mark Ness

The UK's High Court has decided that Richter Gedeon's patent for a single dose of the emergency contraceptive levonorgestrel is invalid in view of a report published a few months before the priority date revealing the preliminary results from an incomplete study of the drug.

Background

Levonorgestrel is the active ingredient in the most commonly employed hormone-based emergency contraceptive. The drug is a synthetic version of the natural hormone progesterone.

Levonorgestrel is currently marketed in the UK by Bayer as Levonelle One Step®. Levonelle One Step® is a tablet containing 1.5 mg of levonorgestrel that is 84% effective as an emergency contraceptive when taken as a single dose 12–72 hours after unprotected intercourse.

Richter Gedeon's patent EP (UK) 1 448 207 had three claims. Claim 1 was directed to a pharmaceutical composition of 1.5 mg levonorgestrel (± 0.2 mg), for use as a single dose. Claim 2 was a claim directed to the same dose of levonorgestrel for use in emergency contraception (in 'Swiss' form in order to comply with EPO law against medical treatment claims), and dependent claim 3 limited that dosage regimen of claim 2 to a single application, administered within 72 hours of unprotected intercourse.

The European patent was granted in 2005 and not opposed centrally at the EPO. In order to kill the EP (UK) patent, Mylan launched an action in the UK High Court seeking revocation. The case dealt only with validity. There was no claim for infringement from Richter Gedeon.

Arguments and judgment

Mylan attacked the patent on two grounds. The primary attack was obviousness, and the secondary attack was insufficiency (non-enabling disclosure). The insufficiency attack was an attempted 'squeeze' argument in case the obviousness attack failed, but since the obviousness attack succeeded, the judgment does not deal with the second attack in detail.

Levonorgestrel was known in the art as an emergency contraceptive. However, the drug was taken in two doses of 0.75 mg, 12 hours apart. The invention in the patent was taking 1.5 mg as one dose. The attack of obviousness concerned a single piece of prior art. This was a report in a special edition of the journal Gynaecology Forum, reporting the highlights of a world congress on gynaecology and obstetrics in Washington DC. The article included a short report of a presentation of the initial results of a medical study comparing the effectiveness of a single dose of 1.5 mg levonorgestrel against two other methods of emergency contraception: (i) two-dose treatment with levonorgestrel; and (ii) another contraceptive. Richter Gedeon had supported the study by providing levonorgestrel.

The subject of the report was noticeably close to the claims, but suffered from three deficiencies:

  1. The three contraceptive methods compared in the study were simply named A, B, and C. The single dose of 1.5 mg levonorgestrel was not identified, presumably because the study was double-blind.
  2. The report consistently stated that the dose of levonorgestrel was 1.5 g (not mg).
  3. The report clearly stated that the study was incomplete, so the results could not be relied on. For example, the report stated:
  • "This study is still in progress but an interim comparison between the groups was presented by Dr von Hertzen."
  • "Dr Glasier advised great caution with [the assumption that a single dose of 1.5 g levonorgestrel was the preferred oral method] as the trial was still incomplete. The last few subjects could alter the data and it was wrong to try to guess which group was which, however tempting this might be."

As regards the unbroken code (formulations A, B and C), the court held that the report still showed that a single dose of levonorgestrel was effective, because the report said that all formulations had similar effectiveness.

As regards the erroneous dose of 1.5 g in the report, Mylan were not able to persuade the court that this would automatically have been read as 1.5 mg. However, Mylan successfully argued that the skilled person would have immediately identified the error and found the real dose elsewhere.

As regards the incomplete nature of the preliminary results, and the consequent caveats at the end of the report, Richter Gedeon attempted to argue that obviousness should be assessed from the view of a medical statistician, who would not have considered the single dose to be effective from these incomplete data. However, the court rejected this argument and held that obviousness should more accurately be assessed from the view of a medical practitioner rather than a statistician. The court held that a practitioner would have considered the one-dose regimen to be a viable form of emergency contraception in view of the report, and that there was then nothing inventive about completing the study. The court held that the invention had been "substantively revealed" as an "obvious likely way forward" by the report.

Comment

The claims related to a specific dosage regimen (a single dose of 1.5 mg), for a specific medical use (emergency contraception). Notably, the court considered the claim to require the dosage regimen to be "reasonably effective" in the medical application. Inventive step then hinged on whether this effectiveness had been revealed in the prior art, with a reasonable expectation of success. Although the preliminary results in the prior art were not watertight, the court found that the conference disclosure had made the regimen seem viably useful, and the patent was revoked for lacking inventive step.

Need advice?

Carpmaels & Ransford LLP is a leading firm of European patent and trade mark attorneys based in London. For more information about our firm and our practice, please visit our website at www.carpmaels.com.

This Briefing Note was first published in the IAM IP Newsletter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions